High Grade Serous Ovarian Cancer Clinical Trials

27 clinical trials for High Grade Serous Ovarian Cancer across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) — RECRUITING · PHASE1
• Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) — RECRUITING · PHASE3
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan — RECRUITING · PHASE1
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types — RECRUITING · PHASE1
• CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer — RECRUITING
• A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib — RECRUITING · PHASE2
• Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer — RECRUITING · PHASE1
• Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging — RECRUITING · NA
• Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma — RECRUITING
• A Phase I Trial of LY3143921 Hydrate in Solid Tumours — COMPLETED · PHASE1
• "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer — NOT_YET_RECRUITING · PHASE2
• Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance — NOT_YET_RECRUITING
• Minimal Residual Disease in Solid Malignancies — NOT_YET_RECRUITING · NA
• 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study — NOT_YET_RECRUITING · NA
• p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 — COMPLETED · PHASE2
• Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian Cancer — COMPLETED
• An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON) — OTHER · PHASE1
• Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) — TERMINATED · PHASE3
• Breast Cancer BRCA1 Carriers: a Pilot Study — WITHDRAWN
• Expanded Access to Veliparib — TERMINATED
• Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer — COMPLETED
• miRNAs in High Grade Serous Ovarian Cancer — OTHER
• NUVOLA TRIAL Open-label Multicentre Study — OTHER · PHASE2
• Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors — COMPLETED · PHASE1
• A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors — COMPLETED · PHASE1

Refine this search